114 related articles for article (PubMed ID: 26173101)
1. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer.
Blute ML; Rushmer TJ; Shi F; Fuller BJ; Abel EJ; Jarrard DF; Downs TM
J Urol; 2015 Nov; 194(5):1214-9. PubMed ID: 26173101
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of bladder cancer recurrence due to bacillus Calmette-Guérin shortage in Brazil.
Murta CB; Hayek KKRE; Dias BC; Yorioka MAW; Cassao VD; Claro JFA
Rev Assoc Med Bras (1992); 2024; 70(5):e20231116. PubMed ID: 38775530
[TBL] [Abstract][Full Text] [Related]
3. Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guérin Therapy?
Karaburun MC; Kuz ED; Akpınar Ç; Obaid K; Göğüş C; Kiremitci S; Enneli D; Baltacı S; Süer E
J Urol; 2024 Jul; 212(1):104-113. PubMed ID: 38690779
[TBL] [Abstract][Full Text] [Related]
4. The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin therapy.
Kikuchi H; Abe T; Miyake M; Miyata H; Matsumoto R; Osawa T; Nishimura N; Fujimoto K; Inokuchi J; Yoneyama T; Tomida R; Numakura K; Matsushita Y; Matsumoto K; Sato T; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Shinohara N
Jpn J Clin Oncol; 2024 Feb; 54(2):192-200. PubMed ID: 37974430
[TBL] [Abstract][Full Text] [Related]
5. Does the quality of endoscopic equipment influence the recurrence rate after photodynamic diagnosis-assisted transurethral resection of bladder tumor?
Nakagawa R; Nohara T; Kano H; Makino T; Naito R; Iwamoto H; Yaegashi H; Kawaguchi S; Shigehara K; Izumi K; Mizokami A
Photodiagnosis Photodyn Ther; 2024 Apr; 46():104023. PubMed ID: 38401816
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
Prasad SM; Huang WC; Shore ND; Hu B; Bjurlin M; Brown G; Genov P; Shishkov D; Khuskivadze A; Ganev T; Marchev D; Orlov I; Kopyltsov E; Zubarev V; Nosov A; Komlev D; Burger B; Raju S; Meads A; Schoenberg M
J Urol; 2023 Oct; 210(4):619-629. PubMed ID: 37548555
[TBL] [Abstract][Full Text] [Related]
7. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance.
Tan WS; Contieri R; Buffi NM; Lughezzani G; Grajales V; Soloway M; Casale P; Hurle R; Kamat AM
J Urol; 2023 Nov; 210(5):763-770. PubMed ID: 37535836
[TBL] [Abstract][Full Text] [Related]
8. Second-look TURBT: evaluation of anatomopatological and oncologic results in a single center.
Maltagliati M; Varca V; Milandri R; Micali S; Bocchialini T; Rocco BMC; Gregori A
Acta Biomed; 2020 May; 91(2):322-325. PubMed ID: 32420968
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guérin in Treating Nonmuscle-Invasive Bladder Cancer.
Kwan ML; Wang Z; Haque R; Lee VS; Roh JM; Ergas IJ; Cannavale KL; Pratt R; Goniewicz M; Loo RK; Aaronson DS; Quesenberry CP; Zhang Y; Ambrosone CB; Kushi LH; Tang L
J Urol; 2024 Jun; ():101097JU0000000000004070. PubMed ID: 38848543
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.
Sabichi AL; Lee JJ; Grossman HB; Liu S; Richmond E; Czerniak BA; De la Cerda J; Eagle C; Viner JL; Palmer JL; Lerner SP
Cancer Prev Res (Phila); 2011 Oct; 4(10):1580-9. PubMed ID: 21881030
[TBL] [Abstract][Full Text] [Related]
11. Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial.
Bryan RT; Pirrie SJ; Abbotts B; Maycock S; During V; Lewis C; Grant M; Bird D; Devall AJ; Wallace DMA; James ND; Billingham LJ; Zeegers MP; Cheng KK;
JAMA Netw Open; 2023 Oct; 6(10):e2337494. PubMed ID: 37847504
[TBL] [Abstract][Full Text] [Related]
12. Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guérin.
Trépanier G; Nykopp T; Rosebush-Mercier R; Gris T; Fadel J; Black PC; Toren P
Clin Genitourin Cancer; 2024 Apr; 22(2):354-359.e1. PubMed ID: 38185610
[TBL] [Abstract][Full Text] [Related]
13. Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey.
Kopenhafer L; Thompson A; Chang J; Sikirica S; Masters ET; Cappelleri JC; Peck EY; Maculaitis MC
Urol Oncol; 2024 Mar; 42(3):70.e1-70.e10. PubMed ID: 38272755
[TBL] [Abstract][Full Text] [Related]
14. Routine Surveillance of Upper Urinary Tract Imaging for Diagnosing Upper Urinary Tract Urothelial Cancer Recurrence in Patients with Nonmuscle Invasive Bladder Cancer.
Nishimura N; Miyake M; Miyamoto T; Shimizu T; Fujii T; Morizawa Y; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K
Adv Urol; 2024; 2024():5894288. PubMed ID: 38807901
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence.
Das S; Gu L; Eve CT; Parrish J; De Hoedt AM; McKee C; Aronson W; Freedland SJ; Williams SB
Clin Genitourin Cancer; 2023 Dec; 21(6):711.e1-711.e6. PubMed ID: 37198099
[TBL] [Abstract][Full Text] [Related]
16. Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
Fukushima H
Int J Urol; 2023 Dec; 30(12):1120-1121. PubMed ID: 37740488
[No Abstract] [Full Text] [Related]
17. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
Pinter M; Weinmann A; Wörns MA; Hucke F; Bota S; Marquardt JU; Duda DG; Jain RK; Galle PR; Trauner M; Peck-Radosavljevic M; Sieghart W
United European Gastroenterol J; 2017 Nov; 5(7):987-996. PubMed ID: 29163965
[TBL] [Abstract][Full Text] [Related]
18. The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A Prospective Study.
Strobach D; Haimerl L; Mannell H; Stief CG; Karl A; Grimm T; Buchner A
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959213
[TBL] [Abstract][Full Text] [Related]
19. ASO Author Reflections: Changes in the Urinary Microbiome After Transurethral Resection of Nonmuscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study.
Ślusarczyk A
Ann Surg Oncol; 2024 Jun; 31(6):3910-3911. PubMed ID: 38602577
[No Abstract] [Full Text] [Related]
20. Perfusion drugs for non‑muscle invasive bladder cancer (Review).
Qian J; Zhang Q; Cao Y; Chu X; Gao Y; Xu H; Cai H; Wu J
Oncol Lett; 2024 Jun; 27(6):267. PubMed ID: 38659423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
